| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
25069 |
| Drug |
House Dust Mite Extract |
| Brand |
Acarizax® |
| Indication |
12 standard quality house dust mite (12 SQ-HDM) sublingual lyophilisate (Acarizax®) is indicated for patients (5-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate-to-severe house dust mite allergic rhinitis despite use of symptom-relieving medication. |
| Rapid review commissioned |
09/12/2025 |
| Rapid review completed |
19/12/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of 12 SQ-HDM for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE |
28/01/2026 |
